BridgeMD
New treatment option for Inflammatory Bowel Disease (IBD)
Official title Study of DISC-0974-201 in Participants With IBD and Anemia
ClinicalTrials.gov ID: NCT07368972
What this study is testing
What is DISC-0974?
DISC-0974 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for inflammatory bowel disease (ibd).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must meet all the following criteria at screening (unless otherwise specified) to be eligible for enrollment in the study:
- Aged ≥18 years at the time of signing informed consent.
- Established diagnosis of IBD (CD, UC, or IBD-unclassified) based on documented findings on both endoscopy and histopathology.
- Baseline endoscopy at screening with modified Mayo Score for UC and CDAI for Crohn's Disease to include mild disease as defined below: a. CDAI of...
- Are symptomatic from anemia as assessed by the Investigator despite optimized, stable conventional IBD-directed therapy for 3 months.
You likely can't join if
- Participants meeting any of the following criteria at screening are not eligible for study enrollment:
- Treatment within 2 days prior to screening with oral iron or iron-containing supplements. Participants may be considered for the study if they...
- Treatment within 30 days prior to screening with any of the following anemia treatments: blood transfusion, EPO-stimulating agent (ESA), or IV iron...
- Planned change in IBD directed therapy within 3 months of screening.
- Moderate or severe IBD assessed during screening period. Defined as:
- CD/IBD-unclassified: participants with a CDAI score ≥220 or SES-CD ≥7
See the full eligibility criteria
Who can join
- Participants must meet all the following criteria at screening (unless otherwise specified) to be eligible for enrollment in the study:
- Aged ≥18 years at the time of signing informed consent.
- Established diagnosis of IBD (CD, UC, or IBD-unclassified) based on documented findings on both endoscopy and histopathology.
- Baseline endoscopy at screening with modified Mayo Score for UC and CDAI for Crohn's Disease to include mild disease as defined below: a. CDAI of \<220 and SES-CD of 0 to 6 (CD/IBD-unclassified) modified Mayo Score of...
- Are symptomatic from anemia as assessed by the Investigator despite optimized, stable conventional IBD-directed therapy for 3 months.
- Hgb ≥7 AND \<12 g/dL for females and ≥7 AND \<13 g/dL for males (local lab) at screening.
- Have symptomatic anemia defined as:
- Hgb ≤10 g/dL and symptomatic as assessed by Investigator (fatigue, shortness of breath at rest or on minimal exertion, palpitations, tachycardia, orthostatic hypotension or dizziness), or
- Hgb \>10 g/dL and a minimum score of 4 on the Numeric Rating Scale for Fatigue.
- Serum ferritin ≥75 μg/L at screening (local lab).
- AST and ALT \<2× upper limit of normal (ULN) at screening.
- Total and direct bilirubin \<ULN at screening.
- Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.
- If female, then EITHER postmenopausal (defined as at least 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) \>40 mIU/mL, or at least 6 weeks following...
- Stable hormonal contraceptive (≥3 months)
- Intrauterine device in place for at least 3 months
- Tubal ligation or single male partner with vasectomy
- If a male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:
- Stable hormonal contraceptive (≥3 months; female partner)
- Intrauterine device in place for at least 3 months (female partner)
- Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
- Confirmed successful vasectomy
- Able to understand and provide written informed consent.
- Able to comply with all study procedures.
What rules you out
- Participants meeting any of the following criteria at screening are not eligible for study enrollment:
- Treatment within 2 days prior to screening with oral iron or iron-containing supplements. Participants may be considered for the study if they undergo a 2-day washout period prior to screening labs for oral iron or...
- Treatment within 30 days prior to screening with any of the following anemia treatments: blood transfusion, EPO-stimulating agent (ESA), or IV iron. Participants may be considered for the study if they undergo a 30-day...
- Planned change in IBD directed therapy within 3 months of screening.
- Moderate or severe IBD assessed during screening period. Defined as:
- CD/IBD-unclassified: participants with a CDAI score ≥220 or SES-CD ≥7
- UC/IBD-unclassified: modified Mayo Score of ≥6 or endoscopic subscore of 3
- Fever, tachycardia, or anticipated need for surgery in the next 3 months
- Hospitalization within 30 days prior to screening.
- Positive direct antiglobulin test with reactive eluate at screening or medical history at screening of active hemolytic anemia.
- Gross gastrointestinal blood loss (eg, visible rectal bleeding, hematochezia, melena) within 4 weeks prior to screening.
- Active gastrointestinal bleeding requiring hospitalization, blood transfusion, or endoscopy hemostasis within 8 weeks prior to screening.
- Current use of Janus kinase (JAK) inhibitor.
- History of hereditary hemochromatosis.
- History of Primary Sclerosis Cholangitis.
- History of hemoglobinopathy or intrinsic RBC defect associated with anemia.
- History of total splenectomy.
- Hematopoietic stem cell or solid organ transplant within the past 10 years.
- Medical history of anemia from Vitamin B12 or folate deficiency or infection in the 3 months prior to screening.
- Stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months prior to screening.
- Medical history of clinically significant thrombotic disorder.
- If female, pregnant or breastfeeding.
- Any major surgery within 8 weeks before screening or incomplete recovery from any previous surgery.
- Current or recent systemic corticosteroid use (within 3 months of screening).
- Endoscopic abnormalities concerning for colon cancer on baseline endoscopy.
- History of malignancy within the last 3 years. The following history/concurrent conditions are allowed: basal or squamous cell carcinoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast...
- Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days of screening.
- A history or known allergic reaction to any investigational product excipients.
- History of ADA formation with anaphylaxis.
- History of inadequately controlled heart failure (New York Heart Association Classification 3 or 4) and/or have a history of left ventricular ejection fraction \<35%.
- Uncontrolled fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement, despite appropriate treatment).
- Active infectious gastroenteritis including clostridium difficile colitis or viral enteritis (eg, cytomegalovirus).
- HIV positive, active hepatitis B virus surface antigen (HBV), or active hepatitis C virus antibody (HCV).
- Significant medical condition, laboratory abnormality, or psychiatric condition that would prevent the patient from participating in the study.
- Any condition or concomitant medication that would confound the ability to interpret data from the study.
The study team makes the final eligibility decision.
Where it's taking place
- Scottsdale, Arizona, United States
- Doral, Florida, United States
- Kissimmee, Florida, United States
- Miami, Florida, United States
- Miami Lakes, Florida, United States
- Tampa, Florida, United States
- St Louis, Missouri, United States
- Cincinnati, Ohio, United States
- Providence, Rhode Island, United States
- Kingwood, Texas, United States
- Sugar Land, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Scottsdale, Arizona, United States; Doral, Florida, United States; Kissimmee, Florida, United States; Miami, Florida, United States; Miami Lakes, Florida, United States; Tampa, Florida, United States and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.